Placebo Vehicle

OTHER14 trials

Sponsors

Pfizer, Boston Scientific Corporation, Ohio State University, Ocular Therapeutix, Inc., Seoul National University Hospital

Conditions

AcneChronic Allergic ConjunctivitisDry EyeDry Eye DiseaseLentigoOcular HypertensionOily SkinOpen Angle Glaucoma

Early Phase 1

The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser

Active, not recruitingNCT02427724

Northwestern UniversityLentigo

Start: 2015-04-30End: 2025-12-31Target: 48Updated: 2025-01-31

Phase 1

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

CompletedNCT04362670

Ocular Therapeutix, Inc.Dry Eye Disease

Start: 2020-04-23End: 2021-08-11Updated: 2023-11-14

Phase 2

Topical CP-690,550 For Chronic Plaque Psoriasis

CompletedNCT00678561

PfizerPsoriasis

Start: 2008-10-13End: 2009-07-24Updated: 2020-12-31

OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

CompletedNCT02062905

Ocular Therapeutix, Inc.Chronic Allergic Conjunctivitis

Start: 2014-03-31End: 2014-11-30Updated: 2019-09-11

OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye

CompletedNCT02468700

Ocular Therapeutix, Inc.Dry Eye

Start: 2015-01-31End: 2015-11-30Updated: 2018-03-29

Phase 3

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

CompletedNCT01072877

Boston Scientific CorporationVaricose Veins

Start: 2010-12-31End: 2012-11-30Updated: 2021-04-21

OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

CompletedNCT02089113

Ocular Therapeutix, Inc.Post-Surgical Ocular Inflammation, Post-Surgical Ocular Pain

Start: 2014-04-30End: 2015-03-31Updated: 2019-09-26

OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

CompletedNCT02445326

Ocular Therapeutix, Inc.Chronic Allergic Conjunctivitis

Start: 2015-04-30End: 2015-09-30Updated: 2018-03-29

OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

CompletedNCT02736175

Ocular Therapeutix, Inc.Post-Surgical Ocular Inflammation, Post-Surgical Ocular Pain

Start: 2015-10-31End: 2016-07-31Updated: 2017-11-13

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

CompletedNCT02914509

Ocular Therapeutix, Inc.Ocular Hypertension, Open Angle Glaucoma

Start: 2016-11-07End: 2019-03-30Updated: 2021-10-11

OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

CompletedNCT02988882

Ocular Therapeutix, Inc.Chronic Allergic Conjunctivitis

Start: 2015-06-30End: 2016-04-27Updated: 2020-10-12

Unknown Phase

Nutrition Blood Outcomes Following Tocotrienol N2B

CompletedNCT01858311

Ohio State UniversityStroke

Start: 2013-03-31End: 2018-12-31Updated: 2021-09-20

Clinical Study for Topical Lupeol in Acne

CompletedNCT02205892

Seoul National University HospitalAcne

Start: 2014-08-31End: 2014-09-30Updated: 2014-09-29

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

CompletedNCT02597777

University of California, DavisOily Skin

Start: 2016-01-31End: 2016-02-29Updated: 2017-04-05

Related Papers

Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.

2022-12-0130 citations